Immunotherapy for prostate cancer: Where we are headed

Giuseppe Schepisi; Alberto Farolfi; Vincenza Conteduca; Filippo Martignano; Delia De Lisi; Giorgia Ravaglia; Lorena Rossi; Cecilia Menna; Salvatore Roberto Bellia; Domenico Barone; Roberta Gunelli; Ugo De Giorgi

doi:10.3390/ijms18122627

Immunotherapy for prostate cancer: Where we are headed

Giuseppe Schepisi, Alberto Farolfi, Vincenza Conteduca, Filippo Martignano, Delia De Lisi, Giorgia Ravaglia, Lorena Rossi, Cecilia Menna, Salvatore Roberto Bellia, Domenico Barone, Roberta Gunelli, Ugo De Giorgi

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Research output: Contribution to journal › Review article › peer-review

Abstract

Prostate cancer is one of the most common malignant neoplasms in men worldwide, and is the fifth cause of cancer-related death. In recent years, a new generation of therapies have been approved for the management of metastatic disease. Moreover, the development of new immunotherapeutic drugs has become a novel frontier for the treatment of several tumor types; to date, numerous studies have investigated their potential activity, including in prostate cancer. In this article, we discuss the role of emerging immunotherapeutic drugs in prostate cancer patients.

Original language	English
Article number	2627
Journal	International Journal of Molecular Sciences
Volume	18
Issue number	12
DOIs	https://doi.org/10.3390/ijms18122627
Publication status	Published - Dec 5 2017

Keywords

Antibodies
CTLA4
Immunotherapy
PD-L1
PD1
Prostate cancer
Vaccines

ASJC Scopus subject areas

Catalysis
Molecular Biology
Spectroscopy
Computer Science Applications
Physical and Theoretical Chemistry
Organic Chemistry
Inorganic Chemistry

Access to Document

10.3390/ijms18122627

Fingerprint Dive into the research topics of 'Immunotherapy for prostate cancer: Where we are headed'. Together they form a unique fingerprint.

Cite this

Immunotherapy for prostate cancer : Where we are headed. / Schepisi, Giuseppe ; Farolfi, Alberto ; Conteduca, Vincenza; Martignano, Filippo; De Lisi, Delia; Ravaglia, Giorgia; Rossi, Lorena; Menna, Cecilia; Bellia, Salvatore Roberto; Barone, Domenico; Gunelli, Roberta; De Giorgi, Ugo.

In: International Journal of Molecular Sciences, Vol. 18, No. 12, 2627, 05.12.2017.

Research output: Contribution to journal › Review article › peer-review

Schepisi, Giuseppe ; Farolfi, Alberto ; Conteduca, Vincenza ; Martignano, Filippo ; De Lisi, Delia ; Ravaglia, Giorgia ; Rossi, Lorena ; Menna, Cecilia ; Bellia, Salvatore Roberto ; Barone, Domenico ; Gunelli, Roberta ; De Giorgi, Ugo. / Immunotherapy for prostate cancer : Where we are headed. In: International Journal of Molecular Sciences. 2017 ; Vol. 18, No. 12.

@article{bcce8219db544a9aa50b82ca89b4eaab,

title = "Immunotherapy for prostate cancer: Where we are headed",

abstract = "Prostate cancer is one of the most common malignant neoplasms in men worldwide, and is the fifth cause of cancer-related death. In recent years, a new generation of therapies have been approved for the management of metastatic disease. Moreover, the development of new immunotherapeutic drugs has become a novel frontier for the treatment of several tumor types; to date, numerous studies have investigated their potential activity, including in prostate cancer. In this article, we discuss the role of emerging immunotherapeutic drugs in prostate cancer patients.",

keywords = "Antibodies, CTLA4, Immunotherapy, PD-L1, PD1, Prostate cancer, Vaccines",

author = "Giuseppe Schepisi and Alberto Farolfi and Vincenza Conteduca and Filippo Martignano and {De Lisi}, Delia and Giorgia Ravaglia and Lorena Rossi and Cecilia Menna and Bellia, {Salvatore Roberto} and Domenico Barone and Roberta Gunelli and {De Giorgi}, Ugo",

year = "2017",

month = dec,

day = "5",

doi = "10.3390/ijms18122627",

language = "English",

volume = "18",

journal = "International Journal of Molecular Sciences",

issn = "1661-6596",

publisher = "MDPI AG",

number = "12",

}

TY - JOUR

T1 - Immunotherapy for prostate cancer

T2 - Where we are headed

AU - Schepisi, Giuseppe

AU - Farolfi, Alberto

AU - Conteduca, Vincenza

AU - Martignano, Filippo

AU - De Lisi, Delia

AU - Ravaglia, Giorgia

AU - Rossi, Lorena

AU - Menna, Cecilia

AU - Bellia, Salvatore Roberto

AU - Barone, Domenico

AU - Gunelli, Roberta

AU - De Giorgi, Ugo

PY - 2017/12/5

Y1 - 2017/12/5

N2 - Prostate cancer is one of the most common malignant neoplasms in men worldwide, and is the fifth cause of cancer-related death. In recent years, a new generation of therapies have been approved for the management of metastatic disease. Moreover, the development of new immunotherapeutic drugs has become a novel frontier for the treatment of several tumor types; to date, numerous studies have investigated their potential activity, including in prostate cancer. In this article, we discuss the role of emerging immunotherapeutic drugs in prostate cancer patients.

AB - Prostate cancer is one of the most common malignant neoplasms in men worldwide, and is the fifth cause of cancer-related death. In recent years, a new generation of therapies have been approved for the management of metastatic disease. Moreover, the development of new immunotherapeutic drugs has become a novel frontier for the treatment of several tumor types; to date, numerous studies have investigated their potential activity, including in prostate cancer. In this article, we discuss the role of emerging immunotherapeutic drugs in prostate cancer patients.

KW - Antibodies

KW - CTLA4

KW - Immunotherapy

KW - PD-L1

KW - PD1

KW - Prostate cancer

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=85037618932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037618932&partnerID=8YFLogxK

U2 - 10.3390/ijms18122627

DO - 10.3390/ijms18122627

M3 - Review article

AN - SCOPUS:85037618932

VL - 18

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 12

M1 - 2627

ER -